Preparation and structure-activity relationship of novel P1/P1′-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 11, 1996, Pages 2156-2169

  Nugiel, David A ^a   Jacobs, Kim ^a   Worley, Tabitha ^a   Patel, Mona ^a   Kaltenbach III, Robert F ^a   Meyer, Dayton T ^a   Jadhav, Prabhakar K ^a   De Lucca, George V ^a   Smyser, Thomas E ^a   Habe, Ronald M ^a   Bacheler, Lee T ^a   Rayner, Marlene M ^a   Seitz, Steven P ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ANTIVIRUS AGENT; HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS(PHENYLMETHYL) 4,7 BIS[(4 AMINOPHENYL)METHYL] 2H 1,3 DIAZAPIN 2 ONE; HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS(PHENYLMETHYL) 4,7 BIS[[4 (METHYLSULFONYL)PHENYL]METHYL] 2H 1,3 DIAZAPIN 2 ONE; HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[[4 (HYDROXYMETHYL)PHENYL]METHYL] 4,7 BIS[3,4 DIFLUOROPHENYL)METHYL] 2H 1,3 DIAZAPIN 2 ONE; N (BENZYLOXYCARBONYL)ALANINE N METHYL N METHOXYAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR INTERACTION; NONHUMAN; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

AZEPINES; BINDING SITES; CELL LINE; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 0029896691     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960083n     Document Type: Article

References (41)

1. Weiss, R. A. How Does HIV Cause AIDS? Science 1993, 260, 1273-79 and references cited therein.
2. Johnston, M. I.; Hoth, D. F. Present Status and Future Prospects of HIV Therapies. Science 1993, 260, 1286-93 and references cited therein.
3. Kohl, N. E.; Emini, E. A.; Schlief, W. A.; Davis, L. J.; Heimbach, J. C.; Dixson, R. A. F.; Scolnik, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acd. Sci. U.S.A. 1988, 85, 4686-90.
4. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schnieder, L.; Kent, S. B. H. Conserved Folding in Retroviral Proteases: Crystal Structure of a Synthetic HIV-1 Protease. Science 1989, 245, 616-21.
5. (a) Parkes, K. E. B.; Bushnell, D. J.; Crackett, P. H.; Dunsdon, S. J.; Freeman, A.C.; Gunn, M. P.; Hopkins, R. A.; Lambert, R. W.; Martin, J. A.; Merrett, J. H.; Redshaw, S.; Spurden, W. C.; Thomas, G. J. Studies Toward the Large-scale Synthesis of the HIV Proteinase Inhibitor Ro 31-8959. J. Org. Chem. 1994, 59, 3656-64 and references cited therein.
6. (b) Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor. J. Med. Chem. 1994, 37, 3443-51.
7. (c) Kempf, D. J.; Marsh, K. C.; Denissen, J.; McDonald, E.; Vasavanonda, S.; Flentge, C.; Green, B. G.; Fino, L.; Park, C.; Kong, X.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Plattner, J. J.; Leonard, J.; Norbeck, D. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease with High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-88.
8. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid Turnover of Plasma Virons and CD4 Lymphocytes in HIV-1 Infection. Nature 1995, 373, 123-6.
9. Thaisrivongs, S. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-44.
10. Urban, J.; Konvalinka, J.; Stehlekova, J.; Gregorova, E.; Majer, P.; Soucek, M.; Andreansky, M.; Fabray, M.; Strop, P. Reduced-Bond Tight-Binding Inhibitors of HIV-1 Protease. FEBS Lett. 1992, 298, 9-13.
11. (a) Thompson, W. J.; Fitzgerald, P. M. D.; Holloway, M. K.; Emini, E. A.; Darke, P. L.; McKeever, B. M.; Schleif, W. A.; Quintero, J. C.; Zugay, J. A.; Tucker, T. J.; Schwering, J. E.; Homnick, C. F.; Nunberg, J.; Springer, J. P.; Huff, J. R. Synthesis and Antiviral Activity of a Series of HIV-1 Protease Inhibitors with Functionality Tethered to the P1 or P1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-701.
12. (b) Young, S. D.; Payne, L. S.; Thompson, W. J.; Gaffin, N.; Lyle, T. A.; Britcher, S. F.; Grahm, S. L.; Schultz, T. H.; Deana, A. A.; Darke, P. L.; Zugay, J. A.; Schleif, W. A.; Quintero, J. C.; Emini, E. A.; Anderson, P. S.; Huff, J. R. HIV-1 Protease Inhibitors Based on Hydroxyethylene Dipeptide Isosteres: An Investigation into the Role of the P1′ Side Chain on Structure-Activity. J. Med. Chem. 1992, 35, 1702-9.
13. Getman, D. P.; DeCrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J.; Mueller, R. A.; Vazquez, M. L.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A. Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere. J. Med. Chem. 1993, 36, 288-91.
14. Budt, K. H.; Peyman, A.; Hansen, J.; Knolle, J.; Meichsner, C.; Paessens, A.; Ruppert, D.; Stowasser, B. HIV Protease Inhibitor HOE/BAY 793, Structure-Activity Relationships in a Series of C2-Symmetric Diols. BioMed. Chem. 1995, 3 (5), 559-71.
15. Lam, P. Y. S.; Jadhav, P. K.; Eyerman, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors Science 1994, 263, 380-4.
16. See: Chang, C.-H.; Schadt, M. C.; Lewandowski, F. A.; DeLoskey, R.; Duke, J.; Calabrese, J. C.; Lam, P. Y. S.; Jadhav, P. K.; Eyerman, C. J.; Hodge, C. N.; Weber, P.C. Three Dimensional Structures of the HIV-1 Protease Complexed with Novel Non-Peptide, Cyclic Urea-Containing Inhibitors. Submitted for publication.
17. Wlodawer, A.; Erickson, J. W. Structure Based Inhibitors of HIV-1 Protease. Annu. Rev. Biochem. 1983, 62, 543-85.
18. Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Viitanen, S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and Dogs. Biopharm. Drug Dispos. 1994, 15, 535-44.
19. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C.-H.; Eyerman, C. J.; Grubb, M.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y. S.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S. DMP 450: An Orally Bioavailable Cyclic Urea Inhibitor of the HIV Protease. Submitted for publication.
20. Lam, P. Y. S.; Ru, Y.; Jadhav, P. K.; Aldrich, P. E.; De Lucca, G. V.; Eyermann, C. J.; Chang, C.-H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Li, R.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.; Jackson, D. A.; Erickson-Viitanen, S.; Hodge, C. N. Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2′ SAR and Molecular Recognition of Cyclic Ureas. Submitted for publication. The preparation of compounds 1 and 2 is also disclosed in this manuscript.
21. (a) Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as Effective Acylating Agents. Tetrahedron Lett. 1981, 22, 3815-8.
22. (b) Angelastro, M. R.; Peet, N. P.; Bey, P. An Efficient Synthesis of Novel α-Diketone and α-Keto Ester Derivatives of N-Protected Amino Acids and Peptides. J. Org. Chem. 1989, 54, 3913-6.
23. 2-Symmetric (1S,2R,3R,4S)-1,4-Diamino 2,3-Diols. J. Org. Chem. 1992, 57, 28-32.
24. 2-Symmetric HIV-1 Protease Inhibitors from D-mannitol. BioMed. Chem. Lett. 1992, 2, 353-6.
25. (a) Levin, J. I.; Turos, E.; Weinreb, S. M. An Alternative Procedure for the Aluminum-Mediated Conversion of Esters to Amides. Synth. Commun. 1982, 12, 989-93.
26. (b) Basha, A.; Lipton, M.; Weinreb, S. M. A Mild, General Method for Conversion of Esters to Amides. Tetrahedron Lett. 1977, 48, 4171-4.
27. The major byproduct isolated is the secondary amine resulting from the Lewis acid-catalyzed Beckmann rearrangement. For example, see: Sasatani, S.; Miyazaki, T.; Maruoka, K.; Yamamoto, H. Diisobutylaluminum Hydride. A Novel Reagent for the Reduction of Oximes. Tetrahedron Lett. 1983, 24 (43), 4711-2.
28. Williams, D. R.; Osterhaut, M. H.; Reddy, J. P. Diastereoselective Reduction of α-Hydroxy Oxime Ethers. Synthesis of syn-1,2-Amino Alcohols. Tetrahedron Lett. 1993, 34 (20), 3271-4.
29. Wiggins, L. F. The Anhydrides of Polyhydric Alcohols. Part II. Derivatives of 1:2-5:6-Dianhydro Mannitol. J. Chem. Soc. 1946, 384-8.
30. 2-Axis of Symmetry. Tetrahedron Lett. 1991, 32, 5729-32.
31. 2-Symmetric and Pseudosymmetric HIV-1 Protease Inhibitors from D-Mannitol and D-Arabitol. BioMed. Chem. Lett. 1991, 1, 219-22.
32. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
33. Yamaguchi, M.; Hirao, I. An Efficient Method for the Alkynylation of Oxiranes Using Alkynyl Boranes. Tetrahedron Lett. 1983, 24(4), 391-4.
34. Converting the alcohol to a good leaving group using p-toluene-sulfonyl chloride, methanesulfonyl chloride, or trifluoromethane-sulfonic anhydride resulted in lower yields favoring the elimination product. Other nitrogen sources (tetramethylguanadinium azide, benzylamine, phthalimide) did not improve the yield.
35. Lipinski, C. A. Bioisosterism in Drug Design. Annu. Rep. Med. Chem. 1986, 21, 283-91.
36. For the preparation of the vanadium trichloride reagent, see: Manzer, L. E. Tetrahydrofuran Complexes of Selected Early Transition Metals. Inorg. Synth. 1982, 21, 135-40.
37. For the preparation of the Zn-Cu couple, see: Smith, R. D.; Simmons, H. E. Norcarane (Bicyclo[4.1.0]heptane). Organic Syntheses; Wiley: New York, 1973; Collect. Vol. No. V, pp 855-858. Alternatively, Zn dust (Aldrich, -325 mesh/<10 μm) can also be used to achieve similar results.
38. 3 at 50°C for 5 h according to Tsuji, T.; Kataoka, T.; Yoshioka, M.; Sendo, Y.; Nishitani, Y.; Hirai, S.; Maeda, T.; Nagata, W. Synthetic Studies on β-Lactam Antibiotics. VII. Mild removal of the Benzyl Ester Protecting Group with Aluminum Trichloride. Tetrahedron Lett. 1979, 30, 2793-6.
39. This compound was prepared by catalytic hydrogenation of the parent unsubstituted cyclic urea used to prepare DMP 323 according to Stocker, J. H. Rhodium-Catalyzed Nuclear Hydrogenation of α-Substituted Benzyl Alcohols and Esters. A Useful Procedure for Establishing Configurations. J. Org. Chem. 1962, 27, 2288-9.
40. Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Potency and Selectivity of Inhibition of the HIV Protease by a Small Nonpeptide Cyclic Urea, DMP 323. Antimicrob. Agents Chemother. 1994, 38, 1628-34.
41. Bacheler, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. An Assay for HIV RNA in Infected Cell Lysates, and Its Use for the Rapid Evaluation of Antiviral Efficacy. Antiviral Chem. Chemother. 1994, 5 (2), 111-21.